IAG to present 3 Abstracts in Oncology Drug Development at ASCO’19
IAG’s Head of Therapeutic Innovation, Dr. Diana Roettger will be attending the American Society of Clinical Oncology (ASCO) at Chicago, USA, June 1-5, 2019. Diana will discuss the challenges biotech companies face in oncology trials and explore IAG’s novel strategies to include advanced imaging biomarkers in the clinical development process. IAG’s scientific team will also present 3 abstracts focusing on multiparametric MRI as a superior methodology for detection of disease progression in various malignant disorders, including high-grade gliomas and solid tumors .
The first abstract, entitled; “Multi-parametric MRI as supplement to mRANO criteria for response assessment to MDNA55 in adults with recurrent or progressive glioblastoma”, showed that multiparametric MRI is a useful adjunct methodology to conventional and modified RANO for the assessment of treatment response, as it allowed for better determination of pseudoprogression by quantitative biomarkers, such as tumor infiltration, edema, and ischemia.
This work has been done in collaboration with Medicenna, who are developing MDNA55 as a novel immunotherapeutic agent and co-authored by IAG’s Diana Roettger and Faiq Shaikh, UCLH’s Sotirios Bisdas, and Medicenna’s Chandtip Chandhasin, Melissa Coello, Nina Merchant, Fahar Merchant, and Martin Bexon.
The second abstract, entitled: “Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors” also explores the effectiveness of mp-MRI and CT in the early therapy response assessment in solid tumors, when used as an adjunct to the CT-based RECIST criteria.
The authors include IAG’s Diana Roettger and Faiq Shaikh, UCLH’s Sotirios Bisdas, and IMV’s Lisa MacDonald, Stephan Fiset, Gabriela Nicola Rosu.
The third abstract, entitled: “Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence” further compares these exploratory techniques to other standardized imaging approaches in cancer imaging. The authors include Sotirios Bisdas, Loizos Shakallis, Andy McEvoy, Anna Miserocchi, George Samandouras, Lewis Thorne, Sebastian Brandner, Jeremy Rees, Naomi Ferscht, Jorge M. Cardoso, Jasmina Panovska-Griffiths, and Carole Sudre from University College London.
These abstracts are examples of our ongoing pursuit of scientific excellence in the field of medical imaging by providing cutting edge imaging techniques and quantitative methodologies for assessment of treatment efficacy, and vetting them through scientific process for robustness and reproducibility.
About IAG, Image Analysis Group
IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise.
IAG takes a holistic approach to biotech’s clinical development and brings together an efficient cloud-based system with embedded quality controls for trial data management (DYNAMIKA), patented methodologies for quantitative assessment of treatment efficacy and safety and expertise to ensure regulatory compliance, drug development and scientific credibility of your data. We ensure that our bio-pharmaceutical clients gain the most benefits of early objective decision making on their treatment efficacy from utilizing advanced imaging techniques in their trials. Speak to us about your program and discover our risk assessment and management strategies to overcome the challenges in your oncology trial by contacting IAG at firstname.lastname@example.org
Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. The 2018 Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. This year’s theme, Delivering Discoveries: Expanding the Reach of Precision Medicine, focuses on making precision medicine a reality by driving progress and expanding its reach so every patient has the chance to benefit. For more information on the conference click here.